Literature DB >> 28077429

Composite End Points in Clinical Trials of Heart Failure Therapy: How Do We Measure the Effect Size?

Paul M Brown1, Justin A Ezekowitz2.   

Abstract

Composite end points are popular outcomes in clinical trials of heart failure therapies. For example, a global rank composite is typically analyzed using a Mann-Whitney U test, and the results are summarized by the mean of ranks and a corresponding P value. The mean of ranks is uninformative, and a clinically meaningful estimate of the treatment effect is needed to communicate study results and facilitate an assessment of heterogeneity (the consistency of the effect across outcomes). The probability index is intuitive for clinicians, easy to calculate, and may be applied to various composites. We suggest a simple and familiar plot to assess heterogeneity across outcomes, which should be routine when analyzing composites. We think that the probability index provides an immediate and simple solution to an overt problem.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  composite end points; heart failure; heterogeneity; probability index

Mesh:

Year:  2017        PMID: 28077429     DOI: 10.1161/CIRCHEARTFAILURE.116.003222

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  7 in total

1.  Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease.

Authors:  Kevin D Hill; H Scott Baldwin; David P Bichel; Alicia M Ellis; Eric M Graham; Christoph P Hornik; Jeffrey P Jacobs; Robert D B Jaquiss; Marshall L Jacobs; Prince J Kannankeril; Jennifer S Li; Rachel Torok; Joseph W Turek; Sean M O'Brien
Journal:  Am Heart J       Date:  2020-05-20       Impact factor: 4.749

2.  Predictors of Posthospital Transitions of Care in Patients With Advanced Cancer.

Authors:  Daniel E Lage; Ryan D Nipp; Sara M D'Arpino; Samantha M Moran; P Connor Johnson; Risa L Wong; William F Pirl; Ephraim P Hochberg; Lara N Traeger; Vicki A Jackson; Barbara J Cashavelly; Holly S Martinson; Joseph A Greer; David P Ryan; Jennifer S Temel; Areej El-Jawahri
Journal:  J Clin Oncol       Date:  2017-10-25       Impact factor: 44.544

Review 3.  Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.

Authors:  Stephen J Greene; Robert J Mentz; Mona Fiuzat; Javed Butler; Scott D Solomon; Andrew P Ambrosy; Cyrus Mehta; John R Teerlink; Faiez Zannad; Christopher M O'Connor
Journal:  Circulation       Date:  2018-09-04       Impact factor: 29.690

4.  A patient-centered composite endpoint weighting technique for orthopaedic trauma research.

Authors:  Ugochukwu N Udogwu; Andrea Howe; Katherine Frey; Marckenley Isaac; Daniel Connelly; Dimitrius Marinos; Mitchell Baker; Renan C Castillo; Gerard P Slobogean; Robert V O'Toole; Nathan N O'Hara
Journal:  BMC Med Res Methodol       Date:  2019-12-26       Impact factor: 4.615

5.  Dual-Task Exercise to Improve Cognition and Functional Capacity of Healthy Older Adults.

Authors:  Naina Yuki Vieira Jardim; Natáli Valim Oliver Bento-Torres; Victor Oliveira Costa; Josilayne Patricia Ramos Carvalho; Helen Tatiane Santos Pontes; Alessandra Mendonça Tomás; Marcia Consentino Kronka Sosthenes; Kirk I Erickson; João Bento-Torres; Cristovam Wanderley Picanço Diniz
Journal:  Front Aging Neurosci       Date:  2021-02-16       Impact factor: 5.750

6.  Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction.

Authors:  Robert J Mentz; David J Whellan; Gordon R Reeves; Amy M Pastva; Pamela Duncan; Bharathi Upadhya; M Benjamin Nelson; Haiying Chen; Shelby D Reed; Paul B Rosenberg; Alain G Bertoni; Christopher M O'Connor; Dalane W Kitzman
Journal:  JACC Heart Fail       Date:  2021-07-07       Impact factor: 12.544

Review 7.  Endpoints in Heart Failure Drug Development.

Authors:  Aliza Hussain; Arunima Misra; Biykem Bozkurt
Journal:  Card Fail Rev       Date:  2022-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.